fashion -WSS

fashion

author：focus 2025-09-30 18:00:52 - browse：9586

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Intellia plays down concerns on accidental germline transmission

WSS

Health officials lay out plans to cope with respiratory virus season

Ventyx halts psoriasis drug development after lackluster trial results

Wegovy improves function in certain heart failure patients

Abortion policy in the spotlight at Republican debate

Vivek Ramaswamy made waves in the debate, much as in biotech

National associations that represent hospice owe an apology

entertainment

fashion

Wikipedia

What does generative AI mean for health care? We asked experts

White House drug czar issues call for 'recovery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA greenlights medical device to combat bladder issues

Medical records are filled with copy

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

As demand for Covid shots wanes, Moderna seeks its next success

Study: Spinal cord stimulation helps patients with paralysis walk again

State Dept. review finds Biden bears some blame for Afghanistan failures

First transplant of an entire human eye performed

explore

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Carbon Health diabetes program, a test of data

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Former Pear Therapeutics executives start new VC firm

Meadows told special counsel he could not recall Trump ever declassifying Mar

As obesity drug market grows, telehealth companies court payers

focus

knowledge

focus

entertainment